<DOC>
	<DOCNO>NCT00338390</DOCNO>
	<brief_summary>The study aim ascertain whether sole replacement tenofovir abacavir day improve immunological response obtain tenofovir + ddI whether good perform double replacement tenofovir ddI abacavir + lamivudine ( joint formulation ) single daily dose achieve objective .</brief_summary>
	<brief_title>Study Evaluate Changes CD4 Replacing TDF With ABC DDI+TDF With ABC+3TC</brief_title>
	<detailed_description>Different work show high rate virological failure among patient abacavir + lamivudine + tenofovir ddI + 3TC + tenofovir , thus render use combination actively unadvisable . Furthermore , recent study also show ABC+3TC associate significantly high increase CD4 current treatment standard form AZT+3TC . This provide u ground suppose patient TDF+ddI may recover CD4 ABC+3HT . Similarly , recently , existence pharmacokinetic interaction tenofovir + abacavir begin question . Finally , replacement tenofovir abacavir tenofovir + ddI abacavir + lamivudine detract potency HAART , toxicity profile different behaviour mitochondrial level similar . This study aim ascertain whether sole replacement tenofovir abacavir day improve immunological response obtain tenofovir + ddI whether good perform double replacement tenofovir ddI abacavir + lamivudine ( joint formulation ) single daily dose achieve objective .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age &gt; 18 year . HIV1 infect patient . Patients triple HAART therapy include ddI + tenofovir plus PI NNRTI least 3 month . Patients undetectable HIV1 viral load ( &lt; 50 copy RNA / mL &lt; centre 's limit detection ) last 6 month . Not treatment immunosuppressive , : hydroxyurea , interferon , ribavirin cytostatics . Not treatment interleukin2 immunomodulators . Women may fertile age ( define least one year menopause undergoing surgical sterilisation technique ) , must undertake use barrier contraceptive method study . Signature informed consent . Incapacity give inform consent . Bad adherence treatment interruption previous 6 month . Prior exposure abacavir . HAART Therapy include ddI dose 400mg + tenofovir weight &gt; 60 kg ddI 250 mg + tenofovir weight &lt; 60 kg . Suspicion cross resistance abacavir lamivudine . Hepatic pancreatic analytical alteration 4 time limit normality . Presence opportunistic infection and/or recent tumour ( &lt; 6 month ) . Patients participate another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Antiretrovirals</keyword>
	<keyword>CD4 cell count</keyword>
	<keyword>toxicity</keyword>
</DOC>